Emerging role for reduced intensity allotransplant in multiple myeloma

Published: June 8, 2009
Abstract Views: 159
PDF: 180
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Allografting for multiple myeloma appears a more potent anti-tumor treatment than autografting with more frequent molecular remissions. However, the curative potential of myeloablative allografting for myeloma patients has not fully been elucidated because of the unacceptably high transplant-related mortality, primarily as a consequence of infection and graft versus host disease. Moreover, as it is performed in patients under 50 years of age, this procedure is only for a minority of myeloma patients. Indeed, mortality rates have decreased in the last decade because of advances in supportive care and a trend toward transplant earlier during the disease course.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Bruno, B., & Boccadoro, M. (2009). Emerging role for reduced intensity allotransplant in multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.437